share gain attract resili end
thermo fisher report robust result beat estim
top bottom line organ revenu growth vs comp
exceed expect jpme partli aid recaptur
order ship pushout data center outag segment
growth led lss organ sd organ modest
benefit divestitur slower grow anatom patholog
busi lp organ ai organ slightli softer
expect ai account revenu impact data center
outag benefit revenu recaptur albeit
difficult comp bottom line adjust ep
also consensu driven top-lin beat bp opm
expans share repurchas look ahead compani
increas full-year guidanc reflect beat also advers fx
environ revenu expect vs
previous ep rang vs
previous chang outlook organ appear
conserv given modestli easier q/q comp one extra day
add overal deliv robust quarter
unpreced tough comp along resili macro risk given
broad-bas busi high consum mix long runway margin
expans bp annual capit deploy option
plan next three year continu like set-up reiter
overweight rate increas dec pt
strong beat organ vs unpreced tough comp
revenu came well consensus/jpm
organ growth vs comp also exceed expect
jpme partli aid recaptur order ship pushout
data center outag tailwind organ growth
organ basi ai grew vs comp driven lc/m sd
vs comp driven transplant immuno-diagnost lss
vs comp driven bioproduct bioscienc lp
vs comp driven pharma servic bioprocess
end market biopharma grew dd note bioprocess grew
impress clinic reacceler hsd academ rebound
msd strength across geographi industri remain sluggish
flat tough comp geograph apac europ grew hsd
china chang outlook europ led
biopharma clinic despit hsd comp na grew msd
bottom line adj ep beat consensus/jpm driven
top-lin beat bp opm expans buyback
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
continu fire cylind organ
inorgan end market continu look exceedingli
healthi despit linger macro/fx/tariff risk
guidanc framework set stage beat-and-
rais year continu like set-up go forward
reiter ow rate
price target price target deriv
discount cash flow analysi capm-deriv
wacc discount rate termin growth
million
cash-flow oper
margin growth
sourc perform driver bloomberg morgan quantit deriv strategi tabl compani data morgan estim
guidanc rais reflect beat also greater fx headwind
term guidanc compani increas midpoint revenu
ep rang reflect beat also advers fx environ
top line revenu expect vs
previous repres organ growth increas
midpoint reflect contribut recent complet gsk api site
acquisit chang outlook organ beat
off-set partial increment fx headwind bottom line
ep rang increas increas
midpoint increas beat lower interest
expens due recent debt refinanc year half cost
prior debt share buyback increment fx
headwind guidanc appear conserv manag assum
result upsid quarter also benefit one extra sell day
sell day typic result revenu impact
one fewer sell day two extra day final
term capit deploy compani repurchas share
manag note pipelin remain highli activ capac
larger deal bolt-on addit potenti asset transfer
pharma similar gsk ireland
maintain overweight overal deliv robust quarter
unpreced tough comp believ tmo strong product leadership key
life scienc applic unmatch commerci scope scale
posit drive continu above-market organ growth
enhanc acquisit brammer see take well deep
dive cell gene therapi biomanufactur along resili
macro risk given broad-bas busi high consum mix long
runway margin expans target bp annual capit deploy
option plan next three year continu like long-
term outlook reiter overweight rate increas decemb
pt previous
lab product servic
 share count
 morgan estim bloomberg compani data
invest thesi valuat risk
continu fire cylind organ inorgan end
market continu look exceedingli healthi despit linger
macro/fx/tariff risk guidanc framework set stage
beat-and-rais year continu like set-up go forward reiter
price target price target deriv discount cash
flow analysi capm-deriv wacc discount rate termin
growth
risk rate price
downsid risk includ deterior global industri demand slow
pharma demand softer academ demand expect given increas
nih budget technolog shortfal includ inabl introduc
competit instrument consum time effect manner
lab product servic
good sold
chang gross margin y/i bp
chang op margin y/i bp
pv termin valu
perpetu growth rate
enterpris valu
thermo fisher scientif summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect research analyst
person view subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report
korea-bas research analyst list front cover applic also certifi per kofia requir analysi
made good faith view reflect opinion without undu influenc intervent
